Apogee Therapeutics, Inc. · NASDAQ:APGE
Apogee Therapeutics — Merger or Acquisition (June 2026)
16 slides from Apogee Therapeutics's merger presentation, Jun 22, 2026
Slide 1: Apogee Has Entered Into a Definitive Agreement To Be Acquired By AbbVie
Apogee Therapeutics + Follow We are pleased to announce that Apogee Therapeutics has entered into a definitive agreement to be acquired by AbbVie for $135.11 per share in cash, with a transaction value of approximately $10.9 billion. As the largest pre-commercial 18 acquisition, this transaction del
Slide 2: Acquisition of Apogee Therapeutics
1 Acquisition of Apogee Therapeutics June 22, 2026
Slide 3: Forward-looking statements
2 June 22, 2026 This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All state
Slide 4: Strong Strategic Fit for AbbVie
3 June 22, 2026 Strong Strategic Fit for AbbVie Complements AbbVie’s Immunology pipeline by adding multiple potentially differentiated assets to treat inflammatory diseases Leverages AbbVie’s regulatory and clinical expertise, commercial capabilities and international infrastructure to maximize Apog
Slide 5: Apogee Overview
4 June 22, 2026 Apogee Overview Clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing for the treatment of atopic dermatitis, asthma and other inflammatory conditions Portfolio of long-acting antibodies targeting well-established biologi
Slide 6: Apogee Well-Aligned With AbbVie Strategic Goals in Immunology
5 June 22, 2026 Apogee Well-Aligned With AbbVie Strategic Goals in Immunology ELEVATE CARE DEVELOP CURES OFFER CONVENIENCE Rinvoq AA, Vitiligo, HS, SLE Lutikizumab HS B-cell Depletion in Rheumatology Skyrizi SubQ Induction in IBD Longer-Acting Antibodies Novel Combinations in Dermatology IL23 / IL1
Slide 7: Apogee Highly Complementary to AbbVie's Immunology Pipeline
6 June 22, 2026 Apogee Highly Complementary to AbbVie’s Immunology Pipeline iv Phase 1 Phase 2 Phase 3 Under Regulatory Review ABBV-313 (IL13/IL31R) Ph1 start Q3 2026 AD ABBV-142 (LPAR1) IPF Lutikizumab (IL1/) HS Rinvoq (JAKi) Alopecia Areata ABBV-319 (CD19 ADC) SLE, SjD ABBV-8736 (TREM1) CD Rinvo
Slide 8: Atopic Dermatitis Large and Growing Therapeutic Area
7 June 22, 2026 Atopic Dermatitis Large and Growing Atopic Dermatitis Therapeutic Area ~$18 billion global revenues growing more than 15% annually ~2.5x more moderate-to-severe patients than psoriasis ~8% penetration for advanced therapies High Unmet Need Only ~20% of patients simultaneously achieve
Slide 9: Zumilokibart (APG777) Extended Half-life Anti-IL13 Antibody
8 June 22, 2026 Zumilokibart (APG777) Extended Half-life Anti-IL13 Antibody Being Developed as a Monotherapy or Combination Therapy in Dermatology, Respiratory and Other Immune-Mediated Diseases Across a robust, reproducible two-part Ph2 study, zumilokibart demonstrated strong lesion and itch contro
Slide 10: Zumilokibart APEX Part B: Higher Absolute Response Rates vs Marketed AD Biologics
9 June 22, 2026 Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part B Numerically Higher Absolute Response Rates and Placebo-Adjusted Efficacy Across Key Endpoints Compared to Currently Marketed AD Biologics 23% 43% Zumi EASI 7 X% Treatment response X% PBO-adjusted X% PBO response 66% s 5 Resp
Slide 11: Zumilokibart APEX Part A: Continuous Improvement Through Week 52
10 June 22, 2026 Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part A Zumilokibart 360mg Q24W Zumilokibart 360mg Q12W Continuous Improvement Across All Endpoints Through Week 52 Zumilokibart 16-Week Induction Zumilokibart 360mg Q24W Zumilokibart 360mg Q12W Durable Maintenance of Responses wit
Slide 12: Asthma Represents a Large and Underserved Market Opportunity
11 June 22, 2026 Asthma Represents a Large and Underserved Market Opportunity to Grow Market with Commercial Investment and Innovation Significant Opportunity in Asthma Market Treatment Options for Type 2 Low Asthma Elevated Efficacy in Type 2 High Asthma Improved Adherence Ongoing exacerbations, st
Slide 13: APG273 Dual IL13 / TSLP Inhibition for Asthma
12 June 22, 2026 APG273 (Zumilokibart + APG333) Dual IL13 / TSLP Inhibition Could Provide Transformational Efficacy for Type 2 High and Low Asthma Patients with Significantly Improved Q12W Dosing Strong Rationale for IL13 / TSLP Combination in Asthma Source: Apogee Corporate Presentation. Note: Data
Slide 14: Transaction and Financial Overview
13 June 22, 2026 Transaction and Financial Overview AbbVie has agreed to acquire all outstanding shares of Apogee for a purchase price of $135.11 per share in an all-cash transaction Premium of approximately 49% to the closing price on June 18, 2026 Purchase price of $10.9B; Implied transaction valu
Slide 15: Key Takeaways
14 June 22, 2026 Key Takeaways A strong strategic fit for AbbVie that represents an attractive opportunity to acquire a pipeline of potentially differentiated assets focused on treating inflammatory conditions Complements AbbVie’s Immunology pipeline by adding a portfolio of long-acting, high-effica
Slide 16: AbbVie
aQobvie
Apogee Therapeutics — Merger or Acquisition (June 2026) on 6ix